A multicenter, phase II, randomized, blinded, placebo-controlled trial evaluating the efficacy and safety of Sutent [sunitinib] with or without bevacizumab in first-line patients with metastatic renal cell cancer
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Adverse reactions
- Acronyms SABRE-R
- Sponsors Genentech
- 14 Apr 2009 Primary endpoint changed from progression-free survival to adverse events, patient numbers amended from 100 to 16 as reported by ClinicalTrials.gov.
- 14 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Aug 2007 Status changed from initiated to recruiting.